BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 30723171)

  • 41. ZY0511, a novel, potent and selective LSD1 inhibitor, exhibits anticancer activity against solid tumors via the DDIT4/mTOR pathway.
    Li Y; Tao L; Zuo Z; Zhou Y; Qian X; Lin Y; Jie H; Liu C; Li Z; Zhang H; Zhang H; Cen X; Yang S; Zhao Y
    Cancer Lett; 2019 Jul; 454():179-190. PubMed ID: 30978443
    [TBL] [Abstract][Full Text] [Related]  

  • 42. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer.
    Giffin MJ; Cooke K; Lobenhofer EK; Estrada J; Zhan J; Deegen P; Thomas M; Murawsky CM; Werner J; Liu S; Lee F; Homann O; Friedrich M; Pearson JT; Raum T; Yang Y; Caenepeel S; Stevens J; Beltran PJ; Canon J; Coxon A; Bailis JM; Hughes PE
    Clin Cancer Res; 2021 Mar; 27(5):1526-1537. PubMed ID: 33203642
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Establishment of A Patient-derived Xenotransplantation Animal Model for Small Cell Lung Cancer and Drug Resistance Model].
    Zhu Y; Huang W; Wu Y; Jia L; Li Y; Chen R; Guo L; Chen Q
    Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):6-14. PubMed ID: 30674387
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative analysis of TTF-1 binding DNA regions in small-cell lung cancer and non-small-cell lung cancer.
    Hokari S; Tamura Y; Kaneda A; Katsura A; Morikawa M; Murai F; Ehata S; Tsutsumi S; Ishikawa Y; Aburatani H; Kikuchi T; Miyazono K; Koinuma D
    Mol Oncol; 2020 Feb; 14(2):277-293. PubMed ID: 31782890
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers.
    Konishi J; Kawaguchi KS; Vo H; Haruki N; Gonzalez A; Carbone DP; Dang TP
    Cancer Res; 2007 Sep; 67(17):8051-7. PubMed ID: 17804716
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study.
    Megyesfalvi Z; Barany N; Lantos A; Valko Z; Pipek O; Lang C; Schwendenwein A; Oberndorfer F; Paku S; Ferencz B; Dezso K; Fillinger J; Lohinai Z; Moldvay J; Galffy G; Szeitz B; Rezeli M; Rivard C; Hirsch FR; Brcic L; Popper H; Kern I; Kovacevic M; Skarda J; Mittak M; Marko-Varga G; Bogos K; Renyi-Vamos F; Hoda MA; Klikovits T; Hoetzenecker K; Schelch K; Laszlo V; Dome B
    J Pathol; 2022 Aug; 257(5):674-686. PubMed ID: 35489038
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs.
    Borromeo MD; Savage TK; Kollipara RK; He M; Augustyn A; Osborne JK; Girard L; Minna JD; Gazdar AF; Cobb MH; Johnson JE
    Cell Rep; 2016 Aug; 16(5):1259-1272. PubMed ID: 27452466
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ASCL1 regulates the expression of the CHRNA5/A3/B4 lung cancer susceptibility locus.
    Improgo MR; Schlichting NA; Cortes RY; Zhao-Shea R; Tapper AR; Gardner PD
    Mol Cancer Res; 2010 Feb; 8(2):194-203. PubMed ID: 20124469
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer.
    Tsuboyama N; Wang R; Szczepanski AP; Chen H; Zhao Z; Shi L; Wang L
    Oncogene; 2022 Apr; 41(15):2152-2162. PubMed ID: 35194152
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
    Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
    Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeted Inhibition of the E3 Ligase SCF
    Zhao H; Iqbal NJ; Sukrithan V; Nicholas C; Xue Y; Yu C; Locker J; Zou J; Schwartz EL; Zhu L
    Cancer Res; 2020 Jun; 80(11):2355-2367. PubMed ID: 32265224
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An integrative transcriptome analysis reveals a functional role for thyroid transcription factor-1 in small cell lung cancer.
    Horie M; Miyashita N; Mattsson JSM; Mikami Y; Sandelin M; Brunnström H; Micke P; Nagase T; Saito A
    J Pathol; 2018 Oct; 246(2):154-165. PubMed ID: 29876935
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oncogene LSD1 is epigenetically suppressed by miR-137 overexpression in human non-small cell lung cancer.
    Zhang X; Zhang X; Yu B; Hu R; Hao L
    Biochimie; 2017 Jun; 137():12-19. PubMed ID: 28223039
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells.
    Cao C; Wu H; Vasilatos SN; Chandran U; Qin Y; Wan Y; Oesterreich S; Davidson NE; Huang Y
    Int J Cancer; 2018 Sep; 143(6):1388-1401. PubMed ID: 29633255
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
    Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
    Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer.
    Szczepanski AP; Zhao Z; Sosnowski T; Goo YA; Bartom ET; Wang L
    Genome Med; 2020 Jul; 12(1):63. PubMed ID: 32669118
    [TBL] [Abstract][Full Text] [Related]  

  • 57. System analysis identifies distinct and common functional networks governed by transcription factor ASCL1, in glioma and small cell lung cancer.
    Donakonda S; Sinha S; Dighe SN; Rao MRS
    Mol Biosyst; 2017 Jul; 13(8):1481-1494. PubMed ID: 28742165
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ASCL1-regulated DARPP-32 and t-DARPP stimulate small cell lung cancer growth and neuroendocrine tumour cell proliferation.
    Alam SK; Wang L; Ren Y; Hernandez CE; Kosari F; Roden AC; Yang R; Hoeppner LH
    Br J Cancer; 2020 Sep; 123(5):819-832. PubMed ID: 32499571
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer.
    Schenk MW; Humphrey S; Hossain ASMM; Revill M; Pearsall S; Lallo A; Brown S; Bratt S; Galvin M; Descamps T; Zhou C; Pearce SP; Priest L; Greenhalgh M; Chaturvedi A; Kerr A; Blackhall F; Dive C; Frese KK
    Nat Commun; 2021 Nov; 12(1):6652. PubMed ID: 34789728
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bromodomain and hedgehog pathway targets in small cell lung cancer.
    Kaur G; Reinhart RA; Monks A; Evans D; Morris J; Polley E; Teicher BA
    Cancer Lett; 2016 Feb; 371(2):225-39. PubMed ID: 26683772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.